BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 55 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)		 PLK2 [1]
(Cell-free assay)		 PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 M3L6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEC3O|Yh|ryP M4DS[XNCVkeHUh?=
ACN M3K4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjWUZpEUUN3ME2wMlAxQDR|IN88US=> M{nJRnNCVkeHUh?=
TE-8 M4SwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEC5OFEh|ryP M3rjdnNCVkeHUh?=
LC-2-ad MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv6TWM2OD1yLkCxNFk{KM7:TR?= NX3mdXNRW0GQR1XS
ALL-PO NUHvUXBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEGzJO69VQ>? MkX0V2FPT0WU
EW-16 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO1TWM2OD1yLkCxN|M3KM7:TR?= Mme4V2FPT0WU
KM12 NHXORm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fmc2lEPTB;MD6wNVM1QCEQvF2= MnnGV2FPT0WU
GI-1 M3LhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED4[JZKSzVyPUCuNFE{QDNizszN M4foS3NCVkeHUh?=
LS-411N NV34U3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m1WmlEPTB;MD6wNVQxPyEQvF2= NUOxSYZvW0GQR1XS
ES8 NGntcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[4OWpKSzVyPUCuNFE1QTRizszN M2HiSHNCVkeHUh?=
SNU-C2B MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGxRpVpUUN3ME2wMlAyPTJ4IN88US=> M13EOHNCVkeHUh?=
CESS M3HhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPqTWM2OD1yLkCxOlAzKM7:TR?= MVjTRW5ITVJ?
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnoZ3pHUUN3ME2wMlAyPjZ6IN88US=> NELSSZZUSU6JRWK=
NCI-H1963 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzZS5ZKSzVyPUCuNFE3PzNizszN NHnFdJFUSU6JRWK=
IA-LM NUC1SVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjiTWM2OD1yLkCxOlg5KM7:TR?= MWDTRW5ITVJ?
SW954 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInHU4ZKSzVyPUCuNFE4ODVizszN M4rzPHNCVkeHUh?=
RL95-2 NWLsTHI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULZfXZyUUN3ME2wMlAyPzN6IN88US=> MnL1V2FPT0WU
LXF-289 NFXzSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPDXpZDUUN3ME2wMlAyPzdizszN NWDxTlE1W0GQR1XS
OCUB-M NFvFVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TGO2lEPTB;MD6wNVgzPiEQvF2= MULTRW5ITVJ?
RKO NEfY[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\aRWlEPTB;MD6wNVk5PyEQvF2= M3jteHNCVkeHUh?=
LOUCY M1zremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2PFBKSzVyPUCuNFIxPSEQvF2= MkjlV2FPT0WU
NOS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEKwPVMh|ryP NXO4SYt1W0GQR1XS
A4-Fuk MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vFWmlEPTB;MD6wNlIyQCEQvF2= NFHIXpdUSU6JRWK=
A388 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPObnFxUUN3ME2wMlAzOjJ5IN88US=> MV\TRW5ITVJ?
TE-9 NFTTOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq2ZodKSzVyPUCuNFIzPjFizszN NE\XfG9USU6JRWK=
KURAMOCHI NF\3OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KwdWlEPTB;MD6wNlI5PSEQvF2= MWDTRW5ITVJ?
KALS-1 NHjsR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLLTYJUUUN3ME2wMlAzOzN6IN88US=> Mo[yV2FPT0WU
HOP-62 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLaOFQxUUN3ME2wMlAzPDJizszN MYPTRW5ITVJ?
RPMI-8402 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TtR2lEPTB;MD6wNlUxQCEQvF2= MYrTRW5ITVJ?
TE-1 NGjxXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn3ZZNGUUN3ME2wMlAzPTF{IN88US=> NXW0T5Z6W0GQR1XS
CCRF-CEM NE\ycY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEK1OFMh|ryP MV\TRW5ITVJ?
HUTU-80 M37oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Wb4dKSzVyPUCuNFI3OjRizszN NHHvNo1USU6JRWK=
NCI-H1648 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPqcFBKSzVyPUCuNFI3PDdizszN MkTtV2FPT0WU
HCE-4 NIfTZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEK2PFIh|ryP MX3TRW5ITVJ?
ETK-1 NY\VOZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHPfpVKSzVyPUCuNFI4OzZizszN NYXmeZlmW0GQR1XS
TE-15 M1rsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTaTWM2OD1yLkCyO|M5KM7:TR?= NV\FfmQyW0GQR1XS
BE-13 M{fq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37FZWlEPTB;MD6wNlc1KM7:TR?= MVPTRW5ITVJ?
KE-37 NG\4XmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXzTWM2OD1yLkCyO|QyKM7:TR?= M1XDUXNCVkeHUh?=
NCI-H1355 NXvqbXNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i2UGlEPTB;MD6wNlc5OyEQvF2= NEj5OmJUSU6JRWK=
TE-11 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEK4NFkh|ryP M{XwenNCVkeHUh?=
BL-70 NXPJV|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHiTWM2OD1yLkCyPFU4KM7:TR?= NXS0SFR2W0GQR1XS
ES6 NHXZ[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX33SXllUUN3ME2wMlAzQDhzIN88US=> NUS5eXdQW0GQR1XS
GT3TKB NX7oT2dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnQTWM2OD1yLkCyPVU{KM7:TR?= MlruV2FPT0WU
LB647-SCLC M{DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEOxPVUh|ryP M1\wR3NCVkeHUh?=
NB13 NVLnVJI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nlbmlEPTB;MD6wN|MyPiEQvF2= NEnrOmhUSU6JRWK=
ST486 M4XvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TYfmlEPTB;MD6wN|M{PyEQvF2= MojDV2FPT0WU
NCI-H82 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfu[ohKSzVyPUCuNFM{PDNizszN M4jvSnNCVkeHUh?=
NTERA-S-cl-D1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnGXZMyUUN3ME2wMlA{Ozl7IN88US=> NWr5R2tLW0GQR1XS
ES4 M2XJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEO0OlMh|ryP M1L0d3NCVkeHUh?=
SK-NEP-1 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfHRpBEUUN3ME2wMlA{PDl7IN88US=> MYDTRW5ITVJ?
Becker M4mxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T0V2lEPTB;MD6wN|U2PSEQvF2= NV3jTotvW0GQR1XS
A101D MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEO3OFgh|ryP NWXFWJh{W0GQR1XS
SK-UT-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEO3O|Qh|ryP NEP1WY1USU6JRWK=
SW982 NXvlN45uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjkTWM2OD1yLkCzO|kh|ryP MUXTRW5ITVJ?
TE-10 M3Htemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzUWpdwUUN3ME2wMlA1ODR4IN88US=> M4fDTXNCVkeHUh?=
OVCAR-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33J[mlEPTB;MD6wOFA2QSEQvF2= NXraS4VsW0GQR1XS
KP-N-YS NYnBfXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnxV49pUUN3ME2wMlA1ODh3IN88US=> MXTTRW5ITVJ?
BL-41 NIPy[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTTTWM2OD1yLkC0NVI2KM7:TR?= NV\SZolpW0GQR1XS
MZ1-PC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfLSJdKSzVyPUCuNFQyOjdizszN M3PlcXNCVkeHUh?=
PF-382 M3jBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGThWmZKSzVyPUCuNFQyQThizszN NUDGeJpTW0GQR1XS
MOLT-13 M1HJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMESyN|gh|ryP NUf4XoRQW0GQR1XS
HCC1599 NYXweXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W0OWlEPTB;MD6wOFI2QCEQvF2= NYn5fG9GW0GQR1XS
IST-MEL1 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\VTWM2OD1yLkC0OFQzKM7:TR?= MW\TRW5ITVJ?
LU-139 M{PY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHzO4x4UUN3ME2wMlA1PDR{IN88US=> NFu5NYtUSU6JRWK=
MS-1 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe2WIhQUUN3ME2wMlA1PzBzIN88US=> M13xdHNCVkeHUh?=
MFH-ino NXzqdFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XPVGlEPTB;MD6wOVAxOyEQvF2= MXfTRW5ITVJ?
IMR-5 NUjIPG9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\wcXJYUUN3ME2wMlA2ODJzIN88US=> MlrPV2FPT0WU
TE-5 NEjOZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEWwOlMh|ryP Ml;iV2FPT0WU
DJM-1 M1rSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXzTWM2OD1yLkC1NVQzKM7:TR?= M{CycnNCVkeHUh?=
NB17 M{\EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvxTJJKSzVyPUCuNFUzODdizszN MUPTRW5ITVJ?
KARPAS-45 NV65eWZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEWzOVgh|ryP Mkm5V2FPT0WU
TGBC1TKB MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljwTWM2OD1yLkC1OFA2KM7:TR?= MlzpV2FPT0WU
ML-2 NYLvOpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TXd2lEPTB;MD6wOVQyPCEQvF2= MorrV2FPT0WU
no-10 NYDJR3A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DuSmlEPTB;MD6wOVQ4PCEQvF2= MX7TRW5ITVJ?
CTV-1 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHPdZd4UUN3ME2wMlA2PTB{IN88US=> MV3TRW5ITVJ?
SJSA-1 M2fMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEW1NkDPxE1? M2HIfXNCVkeHUh?=
HC-1 M3fnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDnUYx6UUN3ME2wMlA2PTl5IN88US=> MoXtV2FPT0WU
TE-12 M{Czemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL0TWM2OD1yLkC1OlE{KM7:TR?= MYnTRW5ITVJ?
KY821 NYDOO|U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLpUldKSzVyPUCuNFU3OzJizszN MYjTRW5ITVJ?
TALL-1 NWrCV2JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HaXmlEPTB;MD6wOVcxQCEQvF2= NYXtd4cyW0GQR1XS
DEL NVjpN3UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrGb5FKSzVyPUCuNFU4ODlizszN NXrnVGVMW0GQR1XS
TE-6 M3zYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PIeGlEPTB;MD6wOVczOiEQvF2= M{P3cHNCVkeHUh?=
SK-LMS-1 NF:0SJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkewTWM2OD1yLkC1PFA2KM7:TR?= MV\TRW5ITVJ?
EW-1 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLaPIlKSzVyPUCuNFU5OzdizszN M4OzcnNCVkeHUh?=
8-MG-BA NWTRdJJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULxUmhjUUN3ME2wMlA2QDVzIN88US=> M4fLZnNCVkeHUh?=
NALM-6 NEG1dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEW5O|Mh|ryP MoK1V2FPT0WU
LB771-HNC NUm5N3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3tNndHUUN3ME2wMlA2QTd7IN88US=> NXrvdYtUW0GQR1XS
HT-144 NFqwOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LnSWlEPTB;MD6wOlE{KM7:TR?= NWPFZ|FCW0GQR1XS
KM-H2 M364bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXKdlJKSzVyPUCuNFYzOjFizszN MYPTRW5ITVJ?
SF268 M1X6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwME[yPFYh|ryP MUXTRW5ITVJ?
RS4-11 NFrpdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwME[zNFQh|ryP M2LEVHNCVkeHUh?=
MHH-PREB-1 M3\xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwME[zNVkh|ryP MomyV2FPT0WU
ATN-1 NWG5Ro91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HoemlEPTB;MD6wOlM1PSEQvF2= NXnQNYpEW0GQR1XS
BB30-HNC NIrRSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwME[0N|Yh|ryP NVP6flhtW0GQR1XS
CPC-N NGXH[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn71TWM2OD1yLkC2OVI1KM7:TR?= NF7IW2NUSU6JRWK=
NB1 NV\ETXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwME[2NVMh|ryP M3fBfXNCVkeHUh?=
KS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[2XIFZUUN3ME2wMlA3PzR6IN88US=> M3;NdXNCVkeHUh?=
RXF393 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLUTmlPUUN3ME2wMlA3PzZ2IN88US=> M2T3enNCVkeHUh?=
IST-SL2 NFPXSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnhWnhKSzVyPUCuNFcxODRizszN MV;TRW5ITVJ?
GI-ME-N M3HaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jwWGlEPTB;MD6wO|I5PiEQvF2= MUfTRW5ITVJ?
VA-ES-BJ M3nZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHUTWM2OD1yLkC3OFc2KM7:TR?= NIHaPJlUSU6JRWK=
NCI-H1581 NGS1bYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[3V5ZKSzVyPUCuNFc1PzhizszN M4DodXNCVkeHUh?=
U-266 NHG0fXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKzV|JxUUN3ME2wMlA4PDl5IN88US=> NUfmTJNHW0GQR1XS
DMS-114 M1fXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLBb5p{UUN3ME2wMlA4PTJ6IN88US=> M3\tUnNCVkeHUh?=
NCI-H187 NF\yWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEe3NlYh|ryP NIfhN|RUSU6JRWK=
SW962 M2PiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPVO21KSzVyPUCuNFc5OzlizszN M4L1PXNCVkeHUh?=
MONO-MAC-6 M13iXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzsTWM2OD1yLkC3PVg3KM7:TR?= NIj4bYNUSU6JRWK=
MOLT-16 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHMTWM2OD1yLkC4NVIyKM7:TR?= NXGxcGc3W0GQR1XS
KNS-42 M2\ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jl[mlEPTB;MD6wPFE3OSEQvF2= MXjTRW5ITVJ?
CMK M{jPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEiyNlUh|ryP MXXTRW5ITVJ?
Ramos-2G6-4C10 NUPEWWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEiyNlUh|ryP M2DqSXNCVkeHUh?=
Daudi NEn5RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PUc2lEPTB;MD6wPFI2PiEQvF2= NUewV3RuW0GQR1XS
NCI-H510A Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvETWM2OD1yLkC4N|M3KM7:TR?= MUPTRW5ITVJ?
LB831-BLC M{PUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H1TGlEPTB;MD6wPFU3OSEQvF2= MmHUV2FPT0WU
HEL Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEi2Olgh|ryP NUHsbXVVW0GQR1XS
LU-134-A NWj2XIJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEi3NFgh|ryP M3XEOXNCVkeHUh?=
NCI-H1694 NWThfWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDITWM2OD1yLkC4O|Q1KM7:TR?= MWrTRW5ITVJ?
KGN NEfKRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH0TWM2OD1yLkC4O|U6KM7:TR?= M2LhZ3NCVkeHUh?=
A253 M3\vZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G1bmlEPTB;MD6wPFgzOiEQvF2= MV\TRW5ITVJ?
DG-75 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5T2lEPTB;MD6wPFkzOiEQvF2= NVjyXJJRW0GQR1XS
MOLT-4 NGfsN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\xWI1KSzVyPUCuNFg6QDNizszN NF;mWZFUSU6JRWK=
NCI-SNU-5 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmyTWM2OD1yLkC5NlU5KM7:TR?= M{DQZ3NCVkeHUh?=
ONS-76 M{jNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEmyO|Yh|ryP M1vtVXNCVkeHUh?=
NCI-H446 NF;CU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfRTWM2OD1yLkC5OFYzKM7:TR?= MX7TRW5ITVJ?
COR-L279 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5bmlEPTB;MD6wPVU2PiEQvF2= MXfTRW5ITVJ?
Calu-6 M3j1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXDTWM2OD1yLkC5OVk5KM7:TR?= M3O5dXNCVkeHUh?=
BC-3 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTnTWM2OD1yLkC5OlYzKM7:TR?= M3;3OXNCVkeHUh?=
NCI-H2126 NVv1VGFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD4b2RWUUN3ME2wMlA6PzlzIN88US=> MX;TRW5ITVJ?
NCI-H1882 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEm4NFkh|ryP M4HLOnNCVkeHUh?=
BB65-RCC MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMUCyPVQh|ryP NEXNdFdUSU6JRWK=
DU-4475 M1i4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13yNGlEPTB;MD6xNFQxPyEQvF2= MVjTRW5ITVJ?
NCI-H526 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMUC0OEDPxE1? NYHx[nVlW0GQR1XS
NEC8 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnZRY93UUN3ME2wMlExPTJ3IN88US=> NIPRcGZUSU6JRWK=
NCI-H1304 NV7rcpRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO1Z2pKSzVyPUCuNVA2QTRizszN MkTaV2FPT0WU
L-540 NVvmUHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXCR|JKSzVyPUCuNVA4ODhizszN M1z2bHNCVkeHUh?=
NCI-SNU-16 NWTDU2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXDVmsxUUN3ME2wMlExPzR{IN88US=> MmPsV2FPT0WU
HD-MY-Z MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvBTWM2OD1yLkGwPFU3KM7:TR?= NHTyTodUSU6JRWK=
K-562 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMUC4OVgh|ryP MnG2V2FPT0WU
JAR NGrjVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrNTWM2OD1yLkGwPVI2KM7:TR?= MV3TRW5ITVJ?
MZ2-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljCTWM2OD1yLkGxNFUh|ryP MnToV2FPT0WU
L-363 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPTWM2OD1yLkGxNFc6KM7:TR?= NX60O3pJW0GQR1XS
BV-173 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfMUZNKSzVyPUCuNVEzPDNizszN M3jTN3NCVkeHUh?=
NCI-H524 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe2PIhKSzVyPUCuNVEzPzRizszN NFm2Z3lUSU6JRWK=
EoL-1-cell MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j6bGlEPTB;MD6xNVY4OiEQvF2= NWPsS2JuW0GQR1XS
K052 M1H0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMUG3NVIh|ryP MVjTRW5ITVJ?
TK10 M1ez[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPRU3VKSzVyPUCuNVE4OjhizszN MkGzV2FPT0WU
KU812 M1HFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W1TWlEPTB;MD6xNlA1PCEQvF2= NH;rV41USU6JRWK=
RPMI-8226 NWLvTGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq2boo4UUN3ME2wMlEzODV{IN88US=> NF7DN5lUSU6JRWK=
MZ7-mel NETCenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGOlBKSzVyPUCuNVIzOzdizszN M3fHR3NCVkeHUh?=
SK-PN-DW MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7CTWM2OD1yLkGyNlg4KM7:TR?= MVvTRW5ITVJ?
SR MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUK0OFEh|ryP M4S3fXNCVkeHUh?=
RPMI-6666 NFfHSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMUK3OFMh|ryP MkDQV2FPT0WU
no-11 M1LuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jxfGlEPTB;MD6xNlg3QSEQvF2= M1XJUHNCVkeHUh?=
EW-3 M3zobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMUK4PVMh|ryP MV\TRW5ITVJ?
LAMA-84 M{\3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOyTWM2OD1yLkGzNVg4KM7:TR?= M{DubXNCVkeHUh?=
HT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jaXmlEPTB;MD6xN|U4PCEQvF2= NXz5O4syW0GQR1XS
KP-N-RT-BM-1 M3fMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXvTWM2OD1yLkGzOlEzKM7:TR?= M1[wOnNCVkeHUh?=
NCI-H747 NHLRZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTITWM2OD1yLkGzO{DPxE1? M4rMcnNCVkeHUh?=
NCCIT MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHmcJRKSzVyPUCuNVM6OzlizszN MVjTRW5ITVJ?
MLMA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO0cYprUUN3ME2wMlE1OTZ5IN88US=> NG\V[ZVUSU6JRWK=
LP-1 NF;NbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;3e|lMUUN3ME2wMlE1OjRizszN NGjpOY1USU6JRWK=
CAL-148 M37odWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDaTWM2OD1yLkG0OFg{KM7:TR?= M1zqUXNCVkeHUh?=
GB-1 M1SxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;HWlQyUUN3ME2wMlE1PTJ4IN88US=> MlLIV2FPT0WU
COR-L88 M4jtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj4eXhMUUN3ME2wMlE1QDB{IN88US=> MWXTRW5ITVJ?
NKM-1 M1j1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFZ|ViUUN3ME2wMlE1QTB4IN88US=> MYrTRW5ITVJ?
NB5 M1zYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMUW0OlIh|ryP M33yXXNCVkeHUh?=
SH-4 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H2UGlEPTB;MD6xOVQ3PiEQvF2= NXWxOY86W0GQR1XS
EM-2 NYnRXoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXYdIV3UUN3ME2wMlE2PDZ5IN88US=> MnvkV2FPT0WU
TGBC24TKB NYLHcGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17WfmlEPTB;MD6xOVY2QSEQvF2= NFjaXZZUSU6JRWK=
SCLC-21H MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUW3NFIh|ryP NF;QToxUSU6JRWK=
COLO-684 M17odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMUW3NlEh|ryP M2jlT3NCVkeHUh?=
KINGS-1 NEjJTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HK[mlEPTB;MD6xOVkyKM7:TR?= MY\TRW5ITVJ?
LS-123 M{DjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHSZoJMUUN3ME2wMlE2QTF5IN88US=> NUf2bJB5W0GQR1XS
MC116 NY[yXYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O4W2lEPTB;MD6xOlE2QCEQvF2= NYTaNJB[W0GQR1XS
SU-DHL-1 M1TZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fybmlEPTB;MD6xOlIxPiEQvF2= MXnTRW5ITVJ?
NCI-H64 NF;Dc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Cy[GlEPTB;MD6xOlM1PyEQvF2= M{Sz[XNCVkeHUh?=
HCE-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17TOWlEPTB;MD6xOlUxPCEQvF2= M1;kW3NCVkeHUh?=
LOXIMVI NEjyPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMU[5OFkh|ryP M{fNNnNCVkeHUh?=
ARH-77 NHfVNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLVUIE3UUN3ME2wMlE4Ozd7IN88US=> MYPTRW5ITVJ?
DOHH-2 NHzNfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HrVmlEPTB;MD6xO|Y4OiEQvF2= M3fYXnNCVkeHUh?=
COLO-320-HSR M2qzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml33TWM2OD1yLkG4NVU1KM7:TR?= MmTCV2FPT0WU
NB6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\JUHhKSzVyPUCuNVg2PjZizszN NY\HOZN6W0GQR1XS
L-428 M3zPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme1TWM2OD1yLkG4PFE{KM7:TR?= NGnLSGZUSU6JRWK=
SNB75 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzsTWM2OD1yLkG4PFI1KM7:TR?= MXvTRW5ITVJ?
NCI-H2141 M3G4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq1b5lKSzVyPUCuNVkxOTFizszN NHvu[VZUSU6JRWK=
KARPAS-299 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2NWlEPTB;MD6xPVI1OSEQvF2= M13nRnNCVkeHUh?=
LC4-1 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXwRY55UUN3ME2wMlE6PTB{IN88US=> NF:4OolUSU6JRWK=
UACC-257 NUPUcGtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLwTWM2OD1yLkG5PVQ4KM7:TR?= NGnmO3RUSU6JRWK=
EVSA-T MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fUNWlEPTB;MD6yNFMyOiEQvF2= M1;TRnNCVkeHUh?=
JiyoyeP-2003 NV\HTY1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jifGlEPTB;MD6yNFQ4PyEQvF2= MYXTRW5ITVJ?
NCI-H720 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrLb3YxUUN3ME2wMlIxPTJ3IN88US=> MYfTRW5ITVJ?
GAK M2i2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMkGxPFkh|ryP MYnTRW5ITVJ?
HH NF3OXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMkG0NFUh|ryP MkLlV2FPT0WU
NCI-H1436 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV64WYhqUUN3ME2wMlIyPDZ2IN88US=> M4jReXNCVkeHUh?=
GR-ST NEO3T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3T2lEPTB;MD6yNVQ5QCEQvF2= M{LYbHNCVkeHUh?=
BC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTEOI1KSzVyPUCuNlI3OTZizszN Mor2V2FPT0WU
SIG-M5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPCTWM2OD1yLkKyO|I4KM7:TR?= NHLmcHNUSU6JRWK=
NCI-H345 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITwdmNKSzVyPUCuNlM5ODVizszN M4j4O3NCVkeHUh?=
OPM-2 NGSwSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvPVmNKSzVyPUCuNlM5QDJizszN M3j2dXNCVkeHUh?=
LB1047-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMkS0NUDPxE1? MX3TRW5ITVJ?
CTB-1 NGDsOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y3[mlEPTB;MD6yOFQ6OyEQvF2= NFXZUFVUSU6JRWK=
A3-KAW MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzWeGg5UUN3ME2wMlI2OzRzIN88US=> MofQV2FPT0WU
SF126 NXro[JozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX1OYRKSzVyPUCuNlU{QDNizszN M4XpUXNCVkeHUh?=
KARPAS-422 NGizR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLEcG9KSzVyPUCuNlU1OzVizszN MkTsV2FPT0WU
MEG-01 NH\hNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2ybGtbUUN3ME2wMlI2Pjd|IN88US=> M{nOV3NCVkeHUh?=
NCI-H209 NX;jRpFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHGSnFqUUN3ME2wMlI3Ozd2IN88US=> NIrvW3BUSU6JRWK=
SBC-1 NITtd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfhTWM2OD1yLkK2OUDPxE1? M1jE[XNCVkeHUh?=
K5 NIHQfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMk[5PFQh|ryP M2rXNnNCVkeHUh?=
QIMR-WIL Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nDPGlEPTB;MD6yO|E2PSEQvF2= NUX4NGpNW0GQR1XS
NMC-G1 NVn6WoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLIU2VWUUN3ME2wMlI5OjF5IN88US=> NIO2b2FUSU6JRWK=
IST-MES1 M1\qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PkUmlEPTB;MD6yPVI{QCEQvF2= M1frR3NCVkeHUh?=
SW684 M1TFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{CwOFch|ryP NIHjc|RUSU6JRWK=
MV-4-11 Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOyTWM2OD1yLkOwO|g5KM7:TR?= M2LSN3NCVkeHUh?=
LAN-6 NF7s[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInqWpdKSzVyPUCuN|E2PzJizszN MlK2V2FPT0WU
RH-1 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XmT2lEPTB;MD6zNVg4OSEQvF2= MVjTRW5ITVJ?
CP66-MEL NVXLN3B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvwTWM2OD1yLkOxPFc5KM7:TR?= MYHTRW5ITVJ?
EC-GI-10 NWTFVGFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwM{K5PFch|ryP Ml3yV2FPT0WU
GDM-1 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwM{OwOVkh|ryP NWTQVFlEW0GQR1XS
IST-SL1 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWwdHBHUUN3ME2wMlM1QTF2IN88US=> NVfqPWVJW0GQR1XS
KMOE-2 NVLyW252T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\RWWlEPTB;MD6zOVE4PSEQvF2= NVLDbHRtW0GQR1XS
OS-RC-2 M3OzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwM{W1OFQh|ryP MUXTRW5ITVJ?
HDLM-2 NV7wdHVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwM{e4NVQh|ryP MmHNV2FPT0WU
DSH1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwM{i2N|Eh|ryP M3fwdnNCVkeHUh?=
LS-1034 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\BW5J7UUN3ME2wMlM5QTV2IN88US=> M131ZXNCVkeHUh?=
LB373-MEL-D NWLac4NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwM{mxPVch|ryP MVfTRW5ITVJ?
GOTO MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:2UmxKSzVyPUCuOFIyOThizszN MmPrV2FPT0WU
MRK-nu-1 NFi3VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D1OmlEPTB;MD60NlIxPSEQvF2= NFrK[2hUSU6JRWK=
SK-MM-2 NILxSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwNEO0OFIh|ryP NETXcWpUSU6JRWK=
BOKU M1HXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjuO4ZoUUN3ME2wMlQ{Pzl{IN88US=> NXzvVFVpW0GQR1XS
NOMO-1 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4TWM2OD1yLkSzPFYh|ryP MVTTRW5ITVJ?
J-RT3-T3-5 NFzKWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPiU|BGUUN3ME2wMlQ1QDd6IN88US=> MmD5V2FPT0WU
COLO-668 NUTmblRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPn[5VOUUN3ME2wMlQ2PjZ6IN88US=> M2TPS3NCVkeHUh?=
SF539 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTp[3RxUUN3ME2wMlQ5Pjh2IN88US=> NHfPNldUSU6JRWK=
LB2518-MEL NIHwem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ZTWM2OD1yLkS5O|A{KM7:TR?= MlXLV2FPT0WU
TE-441-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zs[2lEPTB;MD61NFEzKM7:TR?= NHHWfGdUSU6JRWK=
MDA-MB-134-VI Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf4TWM2OD1yLkWwPVIyKM7:TR?= MY\TRW5ITVJ?
SCC-3 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLL[ZdKSzVyPUCuOVE5PzNizszN M{HUOXNCVkeHUh?=
KLE MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37hPWlEPTB;MD61NlE4OSEQvF2= Mlr5V2FPT0WU
LB2241-RCC Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPPR2RlUUN3ME2wMlUzPTJ3IN88US=> NXuwRY9QW0GQR1XS
NCI-H1417 M37TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ZblhFUUN3ME2wMlU{PDN3IN88US=> M4rFWHNCVkeHUh?=
NCI-H2081 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwNUi2NVEh|ryP MWTTRW5ITVJ?
NCI-H1522 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVryOJp3UUN3ME2wMlU6Ozh|IN88US=> MWjTRW5ITVJ?
NCI-H889 NGjQXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3mTWM2OD1yLkW5PFQ1KM7:TR?= NFrWUm1USU6JRWK=
CGTH-W-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjqfWVKSzVyPUCuOlA4PTVizszN NETEV2tUSU6JRWK=
EB-3 M3r5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD1TWM2OD1yLk[xNVU{KM7:TR?= NV3hW5Z5W0GQR1XS
D-336MG NVPPbHY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\MZ4FKSzVyPUCuOlE4QTFizszN MnjxV2FPT0WU
LC-1F NXznWHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD2SVJKSzVyPUCuOlI2QTJizszN NFv3ZmRUSU6JRWK=
MHH-NB-11 NUTEfpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfnTWM2OD1yLk[zPFAyKM7:TR?= MmTwV2FPT0WU
SK-N-FI NEC5bo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXyxd|ZIUUN3ME2wMlY{QTFizszN MUDTRW5ITVJ?
NCI-H69 M2jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFeoE{UUN3ME2wMlY1QDd7IN88US=> MnLrV2FPT0WU
SCH Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvJTWM2OD1yLk[2NFI{KM7:TR?= MYTTRW5ITVJ?
LS-513 M3vV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCzS3NFUUN3ME2wMlY4OjV7IN88US=> M3u2VXNCVkeHUh?=
CP67-MEL NFXsNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u2OWlEPTB;MD62O|U6PiEQvF2= MU\TRW5ITVJ?
GCIY NVnvdXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f6cmlEPTB;MD63NFM3OyEQvF2= M4HLZnNCVkeHUh?=
SHP-77 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwN{C3N|Qh|ryP M1jHeXNCVkeHUh?=
EHEB NXfVPYhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwN{G4OVQh|ryP NEXV[3lUSU6JRWK=
D-247MG M4HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTXTWM2OD1yLkezNlMzKM7:TR?= Mn\EV2FPT0WU
Raji MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHUToJKSzVyPUCuO|Q6QDlizszN M3zKSXNCVkeHUh?=
MPP-89 NUXYRlBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHYVYxKSzVyPUCuO|U6PzhizszN MkG2V2FPT0WU
EKVX M4DGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL2RnAzUUN3ME2wMlc6ODd|IN88US=> NWO1TIVrW0GQR1XS
HCC2218 NFnOe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrJTWM2OD1yLke5NVMyKM7:TR?= M334[HNCVkeHUh?=
KNS-81-FD MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe2eWxKSzVyPUCuPFExOTFizszN MV\TRW5ITVJ?
HCC2157 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1yLki0PVUyKM7:TR?= MUTTRW5ITVJ?
BT-474 NUPCSFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\sc2lEPTB;MD64PFg2PCEQvF2= NHjTbIhUSU6JRWK=
NCI-H748 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwOUGyJO69VQ>? NWnYSlZlW0GQR1XS
EW-24 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjIPZpKSzVyPUCuPVIxODJizszN NHzoWHVUSU6JRWK=
D-263MG NXrET4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn71TWM2OD1yLkm0OVEzKM7:TR?= MnWxV2FPT0WU
OMC-1 M3\xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwOU[zO|Mh|ryP M17ufnNCVkeHUh?=
NCI-H2196 NGL1S2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXIZVBKSzVyPUCuPVc4PzdizszN NH\6S2RUSU6JRWK=
HAL-01 NEfjToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnywTWM2OD1yLkm5PFczKM7:TR?= NUj4PHhHW0GQR1XS
NCI-H2107 M2rITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMEG4OVQh|ryP M3TsS3NCVkeHUh?=
LB996-RCC NGi4dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf0S5JKSzVyPUGuNFgxPTFizszN NYHMU4V3W0GQR1XS
NCI-H1395 NHzmUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT3[|ZKSzVyPUGuNVA3PyEQvF2= M{LqUHNCVkeHUh?=
CHP-126 M3Gyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwMU[xPVkh|ryP NFrYSnpUSU6JRWK=
NB69 NELiTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXsU5dKSzVyPUGuNlYyPDhizszN MlGxV2FPT0WU
CAS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H2ZmlEPTB;MT6zOFI{OSEQvF2= NYThPYtqW0GQR1XS
JVM-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf4XVJKSzVyPUGuOFc5PTVizszN NWHKPWZPW0GQR1XS
DMS-153 M3vaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37WUGlEPTB;MT61O|Y4PCEQvF2= NHrWW2lUSU6JRWK=
SK-MEL-2 NVW2OVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofsTWM2OD1zLkexO|g6KM7:TR?= MVTTRW5ITVJ?
NCI-H1155 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL2TWM2OD1zLkezOlc3KM7:TR?= NXPZRXFyW0GQR1XS
NCI-H1092 NEjFVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrZcnVKSzVyPUGuO|YyQDJizszN M4\EUHNCVkeHUh?=
LU-165 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\XR45UUUN3ME2xMlg3PDd4IN88US=> Mlj1V2FPT0WU
HL-60 NFfTdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDpTWM2OD1zLkm5PVA5KM7:TR?= MmLXV2FPT0WU
REH MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG4TWM2OD1{LkCwOVgzKM7:TR?= NHrHWFZUSU6JRWK=
JVM-2 M1fld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrxWmxKSzVyPUKuNFYyOzVizszN MUDTRW5ITVJ?
MN-60 NFPO[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G1cWlEPTB;Mj6xO|MxQCEQvF2= M3fzdnNCVkeHUh?=
SCC-15 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\xTGJKSzVyPUKuNlAzPyEQvF2= M4jRTXNCVkeHUh?=
SNU-C1 NGLsZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrZXohZUUN3ME2yMlIyOzR|IN88US=> M1XsSXNCVkeHUh?=
SK-MEL-1 NGTn[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwM{KwOFch|ryP MUPTRW5ITVJ?
TGW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XSNWlEPTB;Mj6zOVAzPyEQvF2= NXTC[GFyW0GQR1XS
CA46 NX\McZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwN{W5Olch|ryP NGHRcGJUSU6JRWK=
NCI-H23 NVzxRVRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;jT2pTUUN3ME2yMlgxPzlzIN88US=> MUjTRW5ITVJ?
MMAC-SF NGHkU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwOE[2Nlgh|ryP MmDqV2FPT0WU
NCI-H2171 M1;ZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDzO4FKSzVyPUOuNFM1PDhizszN NWS1dFhiW0GQR1XS
A704 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPJTWM2OD1|LkG0NVk1KM7:TR?= NYPQVpBHW0GQR1XS
DB MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DTV2lEPTB;Mz6yOVU4PiEQvF2= MVTTRW5ITVJ?
NCI-H719 NHPZOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXhWJpKSzVyPUOuN|A{QDRizszN M1fPbnNCVkeHUh?=
MC-CAR NEjrXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHFSIFKSzVyPUOuOVQ5OTdizszN MoPaV2FPT0WU
SIMA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwNUi0NVYh|ryP MliyV2FPT0WU
SW872 M2Wydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnBTVB3UUN3ME2zMlc5OTBzIN88US=> NGjOUGNUSU6JRWK=
HCC1187 M1HYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PGVWlEPTB;Mz63PFMyPSEQvF2= NVXlR4ZZW0GQR1XS
EW-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnobnRKSzVyPUOuPFM1OTdizszN MnrtV2FPT0WU
NCI-SNU-1 M1;qeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37J[WlEPTB;ND6yNVk6QSEQvF2= MU\TRW5ITVJ?
NCI-H226 NGjseVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfpUnRKSzVyPUSuN|M3ODZizszN MoHpV2FPT0WU
RPMI-8866 NVf1W5g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe2S4Y{UUN3ME20MlM3ODJ7IN88US=> NGCxS2dUSU6JRWK=
OCI-AML2 NW\MTVFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuyb5hjUUN3ME20MlU2OjNizszN M1jDbXNCVkeHUh?=
LU-65 NUfCZ4xIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\QU2lEPTB;ND65N|A{OyEQvF2= NEjFSVhUSU6JRWK=
SK-N-DZ M1;wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHuTWM2OD13Lk[zOFY2KM7:TR?= Mke5V2FPT0WU
NB14 NWWwbJUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTVwOUexN|Uh|ryP M2HCdXNCVkeHUh?=
COLO-829 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP1cppsUUN3ME22MlM{OzV7IN88US=> MXnTRW5ITVJ?
MHH-CALL-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjiTWM2OD14LkWxOVA5KM7:TR?= NInRWYVUSU6JRWK=
NCI-H1770 M3;1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfaRplKSzVyPU[uOlY6ODRizszN NFrZ[lhUSU6JRWK=
ECC4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjQWHRKSzVyPU[uPFIyPzlizszN M3zmXnNCVkeHUh?=
A498 NVftemVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj1dG9CUUN3ME22Mlg4OTl{IN88US=> MX;TRW5ITVJ?
DMS-79 NU\sNZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTmN5VKSzVyPUeuNFQ2OTJizszN NXq5e4ppW0GQR1XS
P30-OHK M1q0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETVUYhKSzVyPUeuNlE6ODZizszN M1;udHNCVkeHUh?=
D-502MG NWXaTFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PaemlEPTB;Nz65PFM3KM7:TR?= M3fJOnNCVkeHUh?=
RCC10RGB NFPD[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LkN2lEPTB;OD6wOlI5KM7:TR?= NH:xToZUSU6JRWK=
U-698-M NXfDO3VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRThwMkmyNlYh|ryP MnXhV2FPT0WU
BB49-HNC M3i2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTlwNEKyOlUh|ryP NIXCRYVUSU6JRWK=
ES1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVizTZdXUUN3ME25MlY5QTV4IN88US=> NH\D[|BUSU6JRWK=
MFM-223 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnJ[WN5UUN3ME2xNE46QTJ5IN88US=> NIKwcYpUSU6JRWK=
C2BBe1 M{\1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hSXV1UUN3ME2xNU4{PTJ|IN88US=> MYXTRW5ITVJ?
EB2 NXzOUY1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF{Lk[4PFEh|ryP M1TvcXNCVkeHUh?=
C8166 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\TXHBKSzVyPUGzMlg{ODNizszN NF[ycXlUSU6JRWK=
ES3 M2fuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC3TWM2OD1zMz65PVc4KM7:TR?= NWPqN5F2W0GQR1XS
NCI-H1650 NHSzXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTlR4lkUUN3ME2xOk4{PzZ3IN88US=> NVj0e|dPW0GQR1XS
Mo-T M1q1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXlbmxKSzVyPUG3MlQxOjlizszN MoKwV2FPT0WU
NB7 NYq0WFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonuTWM2OD1zNz63OFY4KM7:TR?= MnLYV2FPT0WU
ES7 NHnGR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2xcpI4UUN3ME2xPU42PTB5IN88US=> MU\TRW5ITVJ?
ES5 NF71R2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW3fHc2UUN3ME2yNU44PjdzIN88US=> NET6c|ZUSU6JRWK=
MSTO-211H M36yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJzLki4OVgh|ryP NW\Fe4JoW0GQR1XS
U-87-MG Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXPTWM2OD1{NT6xPVY3KM7:TR?= NU\HUWRxW0GQR1XS
THP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m2cmlEPTB;MkmuO|IxOSEQvF2= NVPBNFY5W0GQR1XS
NB10 NFjH[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W4NmlEPTB;M{CuNlY6PCEQvF2= NFnZWm1USU6JRWK=
NH-12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfsWHdZUUN3ME2zN{4zODF5IN88US=> MWXTRW5ITVJ?
COLO-824 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPsS29KSzVyPUO0MlExODZizszN MkWzV2FPT0WU
SKM-1 M2\jT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr5epRKSzVyPUO3Mlg1OjJizszN NVLrXYI6W0GQR1XS
NCI-H1838 NI\CUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPsUHJWUUN3ME2zPE4{Pzl5IN88US=> M1;CVXNCVkeHUh?=
RL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYThTHZWUUN3ME2zPU4zPDd5IN88US=> NUT6O4N2W0GQR1XS
COLO-800 NV;HO3JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW5dWdKSzVyPUSwMlA4PzNizszN NI[yZlFUSU6JRWK=
KG-1 M{PrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HjfGlEPTB;NECuPFk2PSEQvF2= NYHZR2VpW0GQR1XS
TUR NWXQVHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILO[m5KSzVyPUSxMlY{QTlizszN NVvYO4g4W0GQR1XS
LNCaP-Clone-FGC M2DpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP2TWM2OD12MT65NFE4KM7:TR?= M4nOTnNCVkeHUh?=
NCI-H322M M3zXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTR{LkW5PFQh|ryP M4i2ZnNCVkeHUh?=
LNCaP  MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTlzLkOgcm0> MVSyOVUxPTF5NB?=
C4-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRThibl2= M1vwc|I2PTB3MUe0
JURKAT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnKNlQhcA>? NF[5XWJKSzVyPUSxOk43PiCwTR?= NVzoXJRiOjR3MUm5PVU>
MOLT-4 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX3bZI5OjRiaB?= MofrTWM2OD1{OEWzMlUhdk1? M2DyV|I1PTF7OUm1
REH MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[yUWZrOjRiaB?= MoK0TWM2OD1{OEeuOlghdk1? NXrCd2tlOjR3MUm5PVU>
NALM-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOyOEBp NF\VdmxKSzVyPUO0N|MxKG6P M17KPFI1PTF7OUm1
RS 4;11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz4NlQhcA>? NVy3[5ZzUUN3ME21NVkvODVibl2= NVPRNnNqOjR3MUm5PVU>
697 M4D1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO0NlQhcA>? NWfxeFV4UUN3ME2yNVA4NjFibl2= MmW2NlQ2OTl7OUW=
SIL-ALL NX7Jb2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TvWVI1KGh? MXrJR|UxRTF7OT63O{BvVQ>? MlzFNlQ2OTl7OUW=
CEM MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\4PVI1KGh? MXfJR|UxRTV{LkG4JI5O NILkcmczPDVzOUm5OS=>
P12 NYHC[mwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOyOEBp MYfJR|UxRTN7LkK3JI5O NHjsOYgzPDVzOUm5OS=>
NALM-16 M13LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWeyOEBp Ml;VTWM2OD17Nj6yPEBvVQ>? MYOyOFUyQTl7NR?=
JURKAT M2XDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SzR|Q5KGh? MVzJR|UxRTF2Lki0JI5O NXyzVZhROjR3MUm5PVU>
MOLT-4 NELXZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3MOFghcA>? Mn:zTWM2OD1{Nj62JI5O NGfZeoszPDVzOUm5OS=>
REH NWDxTJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq0PEBp NV63e|IyUUN3ME20OE44OSCwTR?= NFvsPGozPDVzOUm5OS=>
NALM-6 NIrWUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULBN|FuPDhiaB?= NWD6XItjUUN3ME2yN{4zPiCwTR?= MV6yOFUyQTl7NR?=
RS 4;11 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rHNVQ5KGh? NHjvZpJKSzVyPUG2OE4zQCCwTR?= M2PpPFI1PTF7OUm1
697 M{DXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG1OFghcA>? MXnJR|UxRTNyNT6zJI5O MXqyOFUyQTl7NR?=
SIL-ALL MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi0PEBp MVvJR|UxRTd2Lk[yJI5O NU\sOXJmOjR3MUm5PVU>
CEM NF7tW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnNOFghcA>? NVrpRXYxUUN3ME2yOE42PSCwTR?= NVjvR3FpOjR3MUm5PVU>
P12 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvZZZI1QCCq MXjJR|UxRTF6LkS2JI5O M2exTFI1PTF7OUm1
NALM-16 NGP2dJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPqOFghcA>? NVvnVoJEUUN3ME22N{4zPCCwTR?= NXzmdWY5OjR3MUm5PVU>
JURKAT NVLyZ3pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LrcVczKGh? MnXLTWM2OD1|Lk[1JI5O MVqyOFUyQTl7NR?=
MOLT-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WwSlczKGh? NYnQUpdWUUN3ME23MlM6KG6P NVKzPINUOjR3MUm5PVU>
REH MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Ww[lczKGh? M4fIU2lEPTB;MU[uNFEhdk1? MoXhNlQ2OTl7OUW=
NALM-6 NYTrXnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofqO|IhcA>? M4PlbWlEPTB;MT63PEBvVQ>? M33rVVI1PTF7OUm1
RS 4;11 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW4O|IhcA>? NUWyeHJDUUN3ME20MlM5KG6P MWqyOFUyQTl7NR?=
697 NWDSbmxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ni[FczKGh? M17vbGlEPTB;N{SuNlghdk1? NY\EN4dDOjR3MUm5PVU>
SIL-ALL M{DOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPjS2Y4OiCq Mmn0TWM2OD15LkKgcm0> NXvHNHhoOjR3MUm5PVU>
CEM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TCUlczKGh? NInXU2hKSzVyPUWuOFIhdk1? Mkf6NlQ2OTl7OUW=
P12 NX3JdIh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHYVJJKPzJiaB?= MUjJR|UxRTZwM{egcm0> MU[yOFUyQTl7NR?=
NALM-16 NYTqV5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL0fWE4OiCq M36wV2lEPTB;N{euO|Mhdk1? NEPOcogzPDVzOUm5OS=>
Y79 NI[1PWxCeG:ydH;zbZMhSXO|YYm= M3fKflEuPTBibl2= NHrRWo8yOi9{NDDo MYnEUXNQ NXPnelVEcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhV NUW2XnBbOjR|Nk[2OlU>
WER-Rb-1 MYXBdI9xfG:|aYOgRZN{[Xl? NFm5UXUyNTVyIH7N NXfRTHNvOTJxMkSgbC=> NVjIR3hITE2VTx?= MWXpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS= NWnnfIZiOjR|Nk[2OlU>
G7 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwPWlEPTB;Mz6zJI5O NHjWSpMzPDJyNEezNy=>
G166 M{\vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOwOnJZUUN3ME23MlAhdk1? MVKyOFIxPDd|Mx?=
CB660 M4riXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4THUGlEPTB;Nj60JI5O NHrsfHYzPDJyNEezNy=>
CB1117 NHywfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF3Lk[gcm0> NXLjc3g{OjR{MES3N|M>
KB-3-1 M{X5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XaOWlEPTB;MT60PEDDuSByLkWzJI5O M4rw[VI{QTZ{NES1
KB-8-5-11 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDNTWM2OD13LkCxJOKyKDJwMEGgcm0> Mn3HNlM6PjJ2NEW=
KB-C-1 NVLRZlNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mxOWlEPTB;MU[uO|YhyrFiND61NUBvVQ>? NVfKUlMzOjN7NkK0OFU>
KB-V-1 NHTSWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ6MT6yOEDDuSB|MT61O{BvVQ>? MWmyN|k3OjR2NR?=
OVCAR-8 M3\rWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi5RpNmUUN3ME23MlE6KMLzIEOuOlAhdk1? M4H4fVI{QTZ{NES1
NCI-ADR-RES MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnRSWtIUUN3ME2xNlc{NjNyINMxJFE6OS5{MDDuUS=> NU\EcZUyOjN7NkK0OFU>
MCF7 M1naNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vTTmlEPTB;NT6xNUDDuSBzLkS3JI5O Mmi1NlM6PjJ2NEW=
MCF7-FLV1000 NXiyVnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3QTWM2OD1|OUOuNVghyrFiN{SuPFMhdk1? NFrNNJAzOzl4MkS0OS=>
S1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDlTWM2OD1{ND6zNEDDuSB2Lke1JI5O NIHXNXUzOzl4MkS0OS=>
S1-M1-80 NEXE[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HLe2lEPTB;Mk[xMlA3KMLzIES4MlI2KG6P Mo\LNlM6PjJ2NEW=
CORL-23/P M4H3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLxOHlKSzVyPUSuN|ghyrFiMT6yOUBvVQ>? NHPob3YzOzl4MkS0OS=>
CORL-23/R NFfxSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvodolTUUN3ME21MlE3KMLzIEGuPFMhdk1? MkPGNlM6PjJ2NEW=
NIH3T3 NYjZUGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e3VWlEPTB;NECuOlAhyrFiND65O{BvVQ>? NVfTOFdwOjN7NkK0OFU>
NIH3T3-G185 NUPyTWRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnFbI5{UUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=> MUmyN|k3OjR2NR?=
pcDNA-HEK293 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwN{WgxtEhOC54NzDuUS=> NYXCN|RLOjN7NkK0OFU>
MDR19-HEK293 M4C2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHwRoZIUUN3ME24OU42OCEEsTCxN{43PyCwTR?= NXv2TWNXOjN7NkK0OFU>
R482-HEK293 NV7nfmZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\FWlMzUUN3ME2yOU46PyEEsTC0Mlk2KG6P Mnn0NlM6PjJ2NEW=
MRP1-HEK293 M2\1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvPN|VyUUN3ME2yMlk6KMLzIEGuOFkhdk1? M2Sze|I{QTZ{NES1
SF188 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNE0yODBibl2= Mli5NlQuQTZiaB?= M4j3cGROW09? MoTybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj2g[IVx\WSnboSgcYFvdmW{ MnXLNlM5QDd4NEW=
T98G MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPJNVAuOTByIH7N NGniNYQzPC17NjDo Ml62SG1UVw>? NIPicm1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDjc45k\W62cnH0bY9vNSCmZYDl[IVvfCCvYX7u[ZI> M{PTbVI{QDh5NkS1
DU145 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK2NFNrTE2VTx?= MX\JR|Ux6oj:NkCgcm0> Ml;TNlM5QDR2Mki=
LNCaP  NIjtT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEixdGlFVVOR MX3JR|Ux6oj:N{Wgcm0> NGXHfJQzOzh6NESyPC=>
PC3 NVj3UWxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LNcWROW09? MXrJR|Ux6oj:MUe1JI5O MVOyN|g5PDR{OB?=
RT4 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrESGV2UUN3ME2yO{4zOSCwTR?= M4nST|I{Pzl{NkO5
5637 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfKWndKSzVyPUS1MlQ4KG6P MU[yN|c6OjZ|OR?=
T24 NXnTVZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTd7LkGyJI5O M1HpbVI{Pzl{NkO5
MCF7  M3fw[GZ2dmO2aX;uJGF{e2G7 MkXwNVAxKG6P NXnPNYoyOSCq NYn2WYs2TE2VTx?= NVLERoY{emWmdXPld{B1cGViaX7keYN1cW:wIH;mxsBIemWkMT|CpHNoczFuwrDQd|ItyqCVZYLwbY5iOyxiYX7kxsBYcXOyMh?= NFjR[GIzOzd5MEK0OC=>
KB-V1  MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITaOmdKSzVyPUOuPVIh|ryP MYKyN|U6OzF7Nh?=
Hec50co MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\ZfGlEPTB;NTDuUS=> NIrlfJUzOzF2Nk[4Oy=>
MDA-MB-468 NYTFWlloSXCxcITvd4l{KEG|c3H5 M2jJSFEwPS9zMDDuUS=> NHXMfogzPC92OD:3NkBp NHPIU4dFVVOR NUfOSlh1cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlqxNlMyPDR{OUS=
MCF10A NXLOW|RySXCxcITvd4l{KEG|c3H5 NX3FOY9JOS93L{GwJI5O Mlz2NlQwPDhxN{KgbC=> NYPlZnF7TE2VTx?= MUDpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX7QUZRwOjNzNESyPVQ>
Huh-7 NEPhXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWixM|ExNzFyMD:xNFAxKG6P M324RVQ5KGh? NVjWO5R1\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCmb4PlMYRmeGWwZHXueIx6 NGPVbFAzOjd2NUW4Oy=>
Daoy  NILXc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\W[VEvQDd3LUK0NEBvVQ>? NHrWbWs4OiCq NH3LO4hFVVOR MlLhTWM2OD13IH7N MWGyNlM6ODJ5OR?=
ONS-76 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGxNU45PzVvMkSwJI5O NGTzT404OiCq NHvtOFhFVVOR Ml3HTWM2OD15LkWgcm0> MYWyNlM6ODJ5OR?=
SUM 149 NE\ZW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMVExOCCwTR?= M4DJN|czKGh? MlTqbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy M2W4b|IzOzB7OUO5
MDA-MB-231 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMVExOCCwTR?= NYe1NYUyPzJiaB?= MWrpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= MVSyNlMxQTl|OR?=
HR5 NHTyXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMVExOCCwTR?= NFrXOGE4OiCq NIn6c4pqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> MYSyNlMxQTl|OR?=
BT-474-M1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn1NE0yODBibl2= NFrkUnI4OiCq NFHYbIFqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> M1;0T|IzOzB7OUO5
AU565 NIfU[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL2NE0yODBibl2= NVXvXYNCPzJiaB?= Mmr6bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy Ml\5NlI{ODl7M{m=
T47D MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETBboExNTFyMDDuUS=> NX3UZpExPzJiaB?= NW\CUYRwcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz M1Hk[FIzOzB7OUO5
MCF7 NV7MeYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PyNlAuOTByIH7N MXi3NkBp NVzicHNMcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz M4\j[lIzOzB7OUO5
HCT116p53(+/+) NWXmblJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTJWmZpOTBvMUCwNEBvVQ>? Ml7DNlQwPDhiaB?= NG\pdYpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>? NH;MZWYzOjJ4MkG3NS=>
HCT116p53(-/-) NYDxbZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:3WFExNTFyMECgcm0> M2f5cVI1NzR6IHi= MmXSbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJkh[XRiMkWgcm0> MmXjNlIzPjJzN{G=
HeLa  NGPNXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFztSnEyOC1zMECgcm0> MV60PEBp NYLs[|RqTE2VTx?= NUe2OVlYUUN3ME21Nk46KG6P M1jXTVIzODhyMkO1
HeLa  M{LoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixNE0yODBibl2= M1XESVczKGh? NUflR5ZuTE2VTx?= NWWw[INMUUN3ME21NE42KG6P MUWyNlA5ODJ|NR?=
GBC NHWzdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nl[|czKGh? NFvm[5ZKSzVyPUG0Mlc5KG6P NHq3ZoIzOTl4NUezPS=>
GB-CL-1 NGPMc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXsVWhsPzJiaB?= M2radmlEPTB;NT6yNkBvVQ>? NETZPY8zOTl4NUezPS=>
Mz-ChA-2 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DwN|czKGh? M1O4NWlEPTB;Mz6zNUBvVQ>? MlmxNlE6PjV5M{m=
TGBC1-TKB NGW0WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuxOFQhcA>? MoLmTWM2OD14LkeyJI5O NGPCUG4zOTl4NUezPS=>
Wittier NUDZd4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvmbWU3PzJiaB?= NILKSppKSzVyPUOuNlYhdk1? NUjUfFBKOjF7NkW3N|k>
H-1 NHfWR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;sOVczKGh? NX\pR3ZNUUN3ME25MlU1KG6P MmXuNlE6PjV5M{m=
HuH-28 NXvIU2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXSNW44OiCq MoXtTWM2OD1zMT6xPUBvVQ>? MViyNVk3PTd|OR?=
NEC NH\QV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DSNFczKGh? MnrjTWM2OD17Lkm4JI5O MWOyNVk3PTd|OR?=
REB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXJToI4OiCq NUL3fI1rUUN3ME2xN{42OSCwTR?= M2XEO|IyQTZ3N{O5
CC-LP-1 M2DwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjOTWFIPzJiaB?= NFTqR4hKSzVyPUWuPFQhdk1? MUOyNVk3PTd|OR?=
CC-SW-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7mO|IhcA>? MXLJR|UxRTlwNUWgcm0> NHzYfIczOTl4NUezPS=>
EGI-1 M2S1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PmZVczKGh? NXTCRWVLUUN3ME2xNE44OiCwTR?= NVXnTGdMOjF7NkW3N|k>
Sk-ChA-1 NH62N2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp MYrJR|UxRTF5LkKgcm0> MYqyNVk3PTd|OR?=
TFK-1 M4LNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TBXVczKGh? Mn30TWM2OD1zMz60OUBvVQ>? NHqwe|EzOTl4NUezPS=>
786-O M3rCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTyb5hLPS16MDDuUS=> MU[5OkBp M2f2W2hEdA>? MYHzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? M4TIbVIyPjR{M{e0
A498 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXNOng2NThyIH7N MkfFPVYhcA>? NH;zXYJJS2x? NVz1bWxpe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N MUKyNVY1OjN5NB?=
ACHN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7OU4g4PS16MDDuUS=> NVe4OW5yQTZiaB?= M2\vS2hEdA>? NGjkUWp{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= Mm\RNlE3PDJ|N{S=
Caki-1 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm1MVgxKG6P NVTETmlyQTZiaB?= MmrsTGNt NGK1cVZ{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= MYKyNVY1OjN5NB?=
SN12C MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi1MVgxKG6P NV\QcpI4QTZiaB?= NYfnO|hsUEOu MVjzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? MVKyNVY1OjN5NB?=
HMC-1.1 M4[w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nFV|EuOTByMDDuUS=> M2nUVlczKGh? NU\CSlZZcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n NVXpNmdwOjF{NEKxPFk>
HMC-1.2 M1\GS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLpPW1[OS1zMECwJI5O M{X2OFczKGh? Ml6zbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m M2DROVIyOjR{MUi5
C2 M2ixUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxMVExODBibl2= NGXTfW84OiCq M3vrXIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>? Ml7vNlEzPDJzOEm=
CHP-212 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG4fZMyNTF{NTDuUS=> M1i2S|I1NTF{MDDo NXvWT3NqcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> NFfTeXUzOTF4OUK0Ni=>
IMR-32 NH;ocndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKV45lOS1zMkWgcm0> MlXiNlQuOTJyIHi= MnrNbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= NHTxfWszOTF4OUK0Ni=>
Kelly MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke5NU0yOjVibl2= MYSyOE0yOjBiaB?= M2H3V4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= NUK1ToRtOjFzNkmyOFI>
SH-EP MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxMVEzPSCwTR?= NWXDZWhuOjRvMUKwJIg> NHvBUZFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l NGDxOIMzOTF4OUK0Ni=>
SH-SY5Y NEK3W45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxMVEzPSCwTR?= MW[yOE0yOjBiaB?= MVnpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n NFjh[nUzOTF4OUK0Ni=>
SK-N-AS MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWxMVEzPSCwTR?= NX33dYxnOjRvMUKwJIg> MVvpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n MV:yNVE3QTJ2Mh?=
SK-N-BE M4TuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfwNU0yOjVibl2= Mo\jNlQuOTJyIHi= NXPOb2s3cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=> M2XDblIyOTZ7MkSy
KG1 M3HqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHxWmoyNzFyL{GwNEBvVQ>? NYixd5kzPzJiaB?= MlH5SG1UVw>? M1HHeIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= NHr0c|IyQTR3OEO1PC=>
U937 M3juUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7uNU8yOC9zMECgcm0> MXi3NkBp M4ThcGROW09? M4PoVIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= MlHUNVk1PTh|NUi=
CAL62 NEPzdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:0XVAxNjFvMUCwJI5O NFvNXpA4OiCq NXz1bmw6TE2VTx?= NWLFNW1ITUN3ME2xMlQhdk1? NXzESGE5OTl{MkO1OVM>
OCUT-1 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDVNE4yNTFyMDDuUS=> NWH4fmxVPzJiaB?= MVPEUXNQ NG\jUYNGSzVyPUKuN{BvVQ>? M{PyOVE6OjJ|NUWz
8505C M2\tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuxOYExNjFvMUCwJI5O MY[3NkBp NXfiV3JTTE2VTx?= NHrafnZGSzVyPUOuNkBvVQ>? NGLTXpYyQTJ{M{W1Ny=>
ACT-1 NXHPU3ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PCNlAvOS1zMECgcm0> MUe3NkBp MX7EUXNQ MUTFR|UxRTVwNDDuUS=> Ml7JNVkzOjN3NUO=
SW1736 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKwMlEuOTByIH7N M2GxblczKGh? NYP4dGVlTE2VTx?= MVvFR|UxRTVwNjDuUS=> NIHPSZQyQTJ{M{W1Ny=>

... Click to View More Cell Line Experimental Data
In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing. 		15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3
CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT02211833 Completed Carcinoma Non-Small-Cell Lung Boehringer Ingelheim October 2006 Phase 1
NCT00701766 Completed Leukemia Myeloid Acute Boehringer Ingelheim October 2006 Phase 2
NCT00706498 Completed Prostatic Neoplasms Boehringer Ingelheim September 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

selleck catalog

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

  • Selective Plk Inhibitors

    GSK461364 : Plk1-selective, Ki=2.2 nM.

  • Plk Inhibitor in Clinical Trial

    Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).

  • Newest Plk Inhibitor

    Ro3280 New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

  • Calssic Plk Inhibitor

    Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products4

  • SBE 13 HCl New

    SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423 New

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • Rigosertib (ON-01910)

    Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

  • HMN-214

    HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

    Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.

  • Volasertib (BI 6727)

    Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

    Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • Ro3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

    Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.

  • NMS-P937 (NMS1286937)

    NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID